Kady Vega
Family · Harlingen, TXNPI 1336694199
Payments from drug & device makers
Across 113 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$547
- Merck$147
- Novo Nordisk$130
- Insulet Corporation$126
- Exact Sciences$122
- Astellas Pharma US Inc$102
- plus $638 from 15 others
What the payments were for
- Food & beverage$1,811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 42 | $547 |
| Merck | 8 | $147 |
| Novo Nordisk | 8 | $130 |
| Insulet Corporation | 8 | $126 |
| Exact Sciences | 6 | $122 |
| Astellas Pharma US Inc | 6 | $102 |
| Bayer | 4 | $88 |
| Amgen | 4 | $72 |
| Boehringer Ingelheim | 4 | $70 |
| Johnson & Johnson | 3 | $68 |
| AbbVie | 3 | $50 |
| AstraZeneca | 3 | $48 |
| GSK | 2 | $39 |
| Dexcom, Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Eisai Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
How this compares
$1,811 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $75,011 |
| JardianceEmpagliflozin | 65 | $73,135 |
| MounjaroTirzepatide | 40 | $49,878 |
| FarxigaDapagliflozin Propanediol | 36 | $48,138 |
| TrulicityDulaglutide | 30 | $32,197 |
| EliquisApixaban | 18 | $28,259 |
| ProliaDenosumab | 16 | $26,890 |
| JanuviaSitagliptin Phosphate | 14 | $18,810 |
| TradjentaLinagliptin | 12 | $9,650 |
| Lagevrio (Eua)Molnupiravir | 11 | $8,261 |
| Atorvastatin Calcium | 324 | $2,932 |
| Losartan Potassium | 234 | $1,943 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 14 | $1,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,523 |
| Gabapentin | 118 | $1,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $547 | $83,60584 claims |
| Boehringer IngelheimJardiance, Tradjenta | $70 | $82,78577 claims |
| Novo NordiskOzempic | $130 | $75,01168 claims |
| AstraZenecaFarxiga | $48 | $48,13836 claims |
| MerckJanuvia, Lagevrio (Eua) | $147 | $27,07025 claims |
| AmgenProlia | $72 | $26,89016 claims |
| AbbVieSynthroid | $50 | $89318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Harlingen
- Laura SaucedoHarlingen$44K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.